Astrana Health, Inc.
ASTH
$30.23
$1.043.55%
| Weiss Ratings | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C+ | |||
| Rating Factors | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.38 | |||
| Price History | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 11.18% | |||
| 30-Day Total Return | -17.90% | |||
| 60-Day Total Return | -19.67% | |||
| 90-Day Total Return | -43.79% | |||
| Year to Date Total Return | -6.12% | |||
| 1-Year Total Return | -24.59% | |||
| 2-Year Total Return | -15.58% | |||
| 3-Year Total Return | -16.68% | |||
| 5-Year Total Return | 216.54% | |||
| 52-Week High % Change | -53.81% | |||
| 52-Week Low % Change | 26.28% | |||
| Price | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $63.20 | |||
| 52-Week Low Price | $23.12 | |||
| 52-Week Low Price (Date) | Feb 28, 2025 | |||
| 52-Week High Price (Date) | Oct 16, 2024 | |||
| Valuation | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.40B | |||
| Enterprise Value | 1.38B | |||
| Price/Earnings (TTM) | 22.49 | |||
| Earnings Per Share (TTM) | 1.30 | |||
| Earnings Per Share Growth | 37.52% | |||
| Price/Earnings To Growth | 0.60 | |||
| Price/Sales (TTM) | 0.82 | |||
| Price/Book (Q) | 1.98 | |||
| Enterprise Value/Revenue (TTM) | 0.80 | |||
| Price | $30.23 | |||
| Enterprise Value/EBITDA (TTM) | 12.62 | |||
| Enterprise Value/EBIT | 16.30 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 48.22M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | 95.76% | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 626 282 0288 | |||
| Address | 1668 S. Garfield Avenue Alhambra, CA 91801 | |||
| Website | www.astranahealth.com | |||
| Country | United States | |||
| Year Founded | 1985 | |||
| Profitability | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 4.92% | |||
| Profit Margin | 3.62% | |||
| Management Effectiveness | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 4.49% | |||
| Return on Equity | 10.26% | |||
| Income Statement | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 14.82M | |||
| Total Revenue (TTM) | 1.72B | |||
| Revenue Per Share | $35.72 | |||
| Gross Profit (TTM) | 259.89M | |||
| EBITDA (TTM) | 109.46M | |||
| EBIT (TTM) | 84.76M | |||
| Net Income (TTM) | 62.46M | |||
| Net Income Avl. to Common (TTM) | 62.46M | |||
| Total Revenue Growth (Q YOY) | 37.49% | |||
| Earnings Growth (Q YOY) | -32.15% | |||
| EPS Diluted (TTM) | 1.30 | |||
| EPS Diluted Growth (Q YOY) | -29.79% | |||
| Balance Sheet | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 350.35M | |||
| Cash Per Share (Q) | $7.27 | |||
| Total Current Assets (Q) | 596.99M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 507.11M | |||
| Current Ratio (Q) | 1.908 | |||
| Book Value Per Share (Q) | $14.75 | |||
| Total Assets (Q) | 1.29B | |||
| Total Current Liabilities (Q) | 312.93M | |||
| Total Debt (Q) | 475.97M | |||
| Total Liabilities (Q) | 778.27M | |||
| Total Common Equity (Q) | 704.62M | |||
| Cash Flow | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -170.50M | |||
| Cash from Financing (TTM) | 162.41M | |||
| Net Change in Cash (TTM) | 74.35M | |||
| Levered Free Cash Flow (TTM) | 124.77M | |||
| Cash from Operations (TTM) | 82.45M | |||
